# A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

> **NCT02060188** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 385 (actual)

## Conditions studied

- Microsatellite Unstable Colorectal Cancer
- Microsatellite Stable Colorectal Cancer
- Mismatch Repair Proficient Colorectal Cancer
- Mismatch Repair Deficient Colorectal Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Cobimetinib
- **DRUG:** Daratumumab
- **DRUG:** BMS-986016

## Key facts

- **NCT ID:** NCT02060188
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-12
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-10-22
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060188, "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02060188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*